.., .. - . 2008; 20: 39-45. : .

. .. - , .. , .. . .: , 2000. .. . . . . 2006; 14(4): 311-317. .. ft- . , . . . 2005; 7: 233-236. .., .. . . , . 2002; 4(2): 46-47. Adinolfi L.E., Utili R., Dilillo M. et al. Intracellular activity of cefamandole and aztreo- nam against phagocytosed Escherichia coli and Staphylococcus aureus. J. Antimicrob. Chemother. 1989; 24: 927-935. Baldwin C.M., Lyseng-Williamson K.A., Keam S.J. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 2008; 68: 803-838. Birnbaum J., Kahan F.M., Kropp H., MacDonald J.S. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am. J. Med. 1985; 78: 3-21. Bustamente C.I., Drusano G.L., Tatem B.A., Sfandiford H.C. Postantibiotic effect of imi- penem on Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1984; 26: 678-682. Carlone N.A., Cuffini A.M., Tullio V., Caval- lo G. Carbapenems and potential immuno- modulating properties. In: Immunotherapy of infections. Ed. by K.N. Masihi. New York: Marcel Dekker, 1994: 167-176. Chen H.Y., Livermore D.M. In vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. J. Antimicrob. Chemother. 1994; 33: 949-958. Cornacchione P., Scaring! L., Capodicasa E.

et al. In vitro effects of meropenem and imipenem/cilastatin on some functions of human natural effector cells.

Chemotherapy 2000; 46: 135-142. Critchley LA., Karlowsky J.A., Draghi D.C.

et al. Activities of Faropenem, an Oral -Lactam, against Recent U.S. Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 2002; 46: 550-555. Dallal M.M., Czachor J.S. Aztreonam-in- duced myelosuppression during treatment of Pseudomonas aeruginosa pneumonia. DICP 1991; 25: 594-597. DeRyke C.A., Banevicius M.A., Fan H.W., Nicolau D.P. Evaluation of the bactericidal activity of meropenem and ertapenem against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob. Agents Chemother. 2007; 51: 1481-1486. Drusano G.L., Sorgel F., Ma L. et al. Pharmacokinetics (PK) and penetration of meropenem (M) into epithelial lining fluid (ELF) in patients with ventilator-associated pneumonia (VAP) Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2004. Abstract A-15. Gettig J.P., Crank C.W., Philbrick A.Ft. Faropenem Medoxomil. Ann. Pharmacoth- er. 2008; 42: 80-90. Goa K.L., Noble S. Panipenem/Betamipron. Drugs 2003; 63: 913-925. Goya T., Torisu M., Doi F., Yoshida T. Effects of granulocyte colony stimulating factor and monobactam antibiotics (Aztreo- nam) on neutrophil functions in sepsis. Clin. Immunol. Immunopathol. 1993; 69: 278284. Gutierrez Fernandez J., Alados Arboledas J.C., Castillo Perez A.M. et al. Changes in phagocytosis of aerobic bacteria by neutrophils after exposure to subinhibitory concentrations of aztreonam and ciprofloxacin. An. Med. Intern. 1990; 7: 63-66.

~\ Gur D., Korten V., Unal S. ef al. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter bau- mannii: report from the Turkish SENTRY Program sites. J. Med. Microbiol. 2008; 57: 1529-1532. Hellinger W.C., Brewer N.S.

Imipenem. Mayo Clin. Proc. 1991; 66: 1074-1081. Hellinger W.C., Brewer N.S. Carbapenems and monobactams: imipenem, meropenem, and az- treonam. Mayo Clin. Proc. 1999; 74: 420-434. Kahan F.M., Kropp H., Sundelof J.G., Birn- baum J. Thienamycin: development of imi- penen-cilastatin. J. Antimicrob. Chemother. 1983; 12: 1-35. Ikawa K., Morikawa N., Ikeda K. et al. Population pharmacokinetics and pharmacodynamics of biapenem in paediatric patients. J. Clin. Pharm. Ther. 2008; 33: 203-210. Keam S.J. Doripenem: a review of its use in the treatment of bacterial infections. Drugs 2008; 68: 2021-2057. Kropp H., Gerckens L., Sundelof J.G., Kahan F.M. Antibacterial activity of imipenem: the first thienamycin antibiotic. Rev. Infect. Dis. 1985; 7: 389-410. Kufi J.L., Nightingale C.H., Knauft R.F., Nicolau D.P. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin. Ther. 2004; 26: 493-501. Koomanachai P., Crandon J.L., Kuti J.L., Nicolau D.P. Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program. Int. J. Antimicrob. Agents 2009; 33: 348-353. Lingaas E., Midlvedt T. The influence of ce- foperazone, cefotaxime, ceftazidime and az- treonam on phagocytosis by human neutrophils in vitro. J. Antimicrob. Chemother. 1989; 23: 701-710. Lister P.D. Carbapenems in the USA: focus on doripenem. Exp. Rev. Antiinfect. Ther. 2007; 5: 793-809. Lorente L., Lorenzo L., Martin M.M. et al.

Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to Gram-negative bacilli. Ann. Pharmacother. 2006; 40: 219-223. Lyon J.A. Imipenem/cilastatin: the first carbapenem antibiotic. Drug Intell. Clin. Pharm. 1985; 19: 895-899. Matera G., Berlinghieri M.C., Foca A. Meropenem: effects on human leukocyte function and interleukin release. Int. J. Antimicrob. Agents 1995; 5: 129-133. Mattoes H.M., Kuti J.L., Drusano G.L., Nicolau D.P.

Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin. Ther. 2004; 26: 1187-1198. Muto Y., Mikami Y., Sakakibara S. etal. Pharmacokinetic and pharmacodynamic properties of biapenem, a carbapenem antibiotic, in rat experimental model of severe acute pancreatitis. Pancreas 2008; 36:125-132. NaruseS., Wang Y., KitagawaM. etal. Longterm effects of nafamostat and imipenem on experimental acute pancreatitis in rats. Pancreas 2000; 21: 290-295. Nicolau D.P. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin. Infect. Dis. 2008; 15: 32-40. Nicolau D.P. Pharmacodynamic optimization of /3-lactams in the patient care setting. Crit. Care 2008; 12: 2. Nicolau D.P. Carbapenems: a potent class of antibiotics. Exp. Opin. Pharmacother. 2008; 9: 23-37. Ohashi N., Uematsu T., Nagashima S. et al.

Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease. J. Infect. Chemother. 2005; 11: 24-31. Ortega E., de Pablo M.A., Gallego ./VI. et al. Effects of aztreonam on natural immunity in mice. Int. J. Antimicrob. Agents 1999; 13: 41-46. Pruul H., Lewis G., McDonald P.J. Enhanced susceptibility of gram-negative bacteria to phagocytic killing by human polymorphonuclear leucocytes after brief exposure to aztreonam. J. Antimicrob. Chemother. 1988; 22: 675-686. Rahman M.U., Mazumder A. The immunomodulatory effects of gentamicin, imipenem, piperacillin and amphotericin on LAK effector function in vitro. FEMS Immunol. Med. Microbiol. 2001; 30: 249-252. Rodriguez A.., Barriga C., De la Fuente M.

Stimulation of phagocytic processes and antibody-dependent cellular cytotoxicity of human neutrophils by cefmetazole, Microbiol. Immunol. 1991; 35: 545-556. Rodriguez A.B., Barriga C., De la Fuente M. Mechanisms of action involved in the chemoattractant activity of three /3-lactamic antibiotics upon human neutrophils. Bio- chem. Pharmacol. 1991; 41: 931936. Rodriguez A.B., Hernanz A., De la Fuente M. Effect of three /3-lactam antibiotics on ascorbate content, phagocytic activity and superoxide anion production in human neutrophils. Cell Physiol. Biochem. 1991; 1: 170 176. Rodriguez A.B., Sanchez C., Barriga C. Effect of aztreonam upon human polymorphonuclear leukocyte functions. Comp. Immunol. Microbiol. Infect. Dis. 1992; 15: 131-136. Sato K., Sato N., Shimizu H. et al. Faropen- em enhances superoxide anion production by human neutrophils in vitro. J. Antimicrob. Chemother. 1999; 44: 337-341. Scheffer J., Koller J., Cullmann W., Konig W. Effects of cefaclor, cefetamet and RO 40-6890 on inflammatory response of human granulocytes. J. Antimicrob. Chemother. 1992; 30: 57-66. Schwarz ˲., Poch B., Isenmann R. et al. Effect of early and late antibiotic treatment in experimental acute pancreatitis in rats. Lan- genbecks Arch. Surg. 2007; 392: 365-730. Shah P.M. Parenteral carbapenems. Clin. Microbiol. Infect. 2008; 14: 175-180. Siegert R., Berg O., Gebanno P. et al. Comparison of the efficacy and safety of farope- nem daloxate and cefuroxime axetil for the treatment of acute bacterial maxillary sinusitis in adults. Eur. Arch. Oto-Rhino-Lar- ingol. 2003; 260: 186-194. Simon D.M., Koenig G., Trenholme G.M. Differences in release of tumor necrosis factor from THP-1 cells stimulated by filtrates of antibiotic-killed Escherichia coli. J. Infect. Dis. 1991; 164: 800-802. Stone K.C., Dagan R., Arguedas A. et al. Activity of Faropenem against Middle Ear Fluid Pathogens from Children with Acute Otitis Media in Costa Rica and Israel. Antimicrob. Agents Chemother. 2007; 51: 2230-2235. Thalhammer F., Traunmuller F., El Menyawi et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J. Antimicrob. Chemother. 1999; 43: 523-527. Thompson R.L. Cephalosporin, earbapen- em, and monobactam antibiotics. Mayo Clin. Proc. 1987; 62: 821-834. Toynaga Y., Ishihara T., Tezuka T. et al. Pharmacokinetic and clinical studies on bi- apenem (L-627) in the pediatric field. Japan.

J.  Antibiot. 1995; 47: 1691-1705. Velluti G., Garuti G.C., Bonucchi M.E. etal. Activity of aztreonam in pneumology, Part 2: Influence on phagocytosis and intracellular killing of human alveolar macrophages. J. Chemother. 1994; 6: 44-49. Zhanel G.G., Johanson C., Embil J.M. et al. Ertapenem: review of a new carbapenem. Exp. Rev. Antiinfect. Ther. 2005; 3: 23-39. Zhanel G.G., Wiebe R., Dilay L. et al. Comparative review of the carbapenems. Drugs 2007; 67: 1027-1052

<< | >>
: .. , .. , .. . 2012. 2012


- - - -
- - - - - - - - - - - - - -